 Ernesto Sparrelid
Concepts (459)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 70 | 2026 | 276 | 12.920 |
Why?
| | Liver Neoplasms | 56 | 2026 | 785 | 9.920 |
Why?
| | Portal Vein | 30 | 2026 | 114 | 7.190 |
Why?
| | Bile Duct Neoplasms | 25 | 2026 | 130 | 6.140 |
Why?
| | Pancreatic Neoplasms | 36 | 2026 | 928 | 5.850 |
Why?
| | Liver Failure | 17 | 2025 | 83 | 5.270 |
Why?
| | Pancreatectomy | 31 | 2026 | 285 | 4.930 |
Why?
| | Cholangiocarcinoma | 17 | 2026 | 108 | 4.710 |
Why?
| | Colorectal Neoplasms | 24 | 2026 | 849 | 4.170 |
Why?
| | Embolization, Therapeutic | 10 | 2026 | 242 | 4.010 |
Why?
| | Carcinoma, Pancreatic Ductal | 14 | 2026 | 292 | 3.750 |
Why?
| | Liver | 28 | 2026 | 1893 | 3.090 |
Why?
| | Postoperative Complications | 47 | 2026 | 2938 | 2.710 |
Why?
| | Adenocarcinoma, Mucinous | 4 | 2022 | 76 | 2.700 |
Why?
| | Klatskin Tumor | 14 | 2026 | 18 | 2.600 |
Why?
| | Pancreaticoduodenectomy | 14 | 2026 | 135 | 2.180 |
Why?
| | Pancreatic Fistula | 12 | 2026 | 35 | 2.030 |
Why?
| | Carcinoma, Hepatocellular | 10 | 2026 | 373 | 1.960 |
Why?
| | Liver Regeneration | 8 | 2025 | 46 | 1.890 |
Why?
| | Robotic Surgical Procedures | 7 | 2026 | 183 | 1.730 |
Why?
| | Retrospective Studies | 85 | 2026 | 17149 | 1.700 |
Why?
| | Biliary Tract Neoplasms | 5 | 2025 | 31 | 1.490 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2022 | 11 | 1.480 |
Why?
| | Aged | 82 | 2026 | 26001 | 1.440 |
Why?
| | Bile Ducts, Intrahepatic | 7 | 2024 | 63 | 1.290 |
Why?
| | Middle Aged | 88 | 2026 | 36021 | 1.270 |
Why?
| | Sweden | 18 | 2026 | 111 | 1.230 |
Why?
| | Neoadjuvant Therapy | 10 | 2026 | 463 | 1.230 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2025 | 28 | 1.230 |
Why?
| | Humans | 174 | 2026 | 145305 | 1.170 |
Why?
| | Prognosis | 26 | 2026 | 4310 | 1.130 |
Why?
| | Bone Marrow Transplantation | 15 | 2000 | 294 | 0.940 |
Why?
| | Liver Diseases | 4 | 2026 | 305 | 0.930 |
Why?
| | Hospitals, High-Volume | 1 | 2026 | 50 | 0.930 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2026 | 58 | 0.900 |
Why?
| | Survival Rate | 21 | 2026 | 2100 | 0.890 |
Why?
| | Male | 89 | 2026 | 72628 | 0.870 |
Why?
| | Female | 89 | 2026 | 78605 | 0.830 |
Why?
| | Cysts | 1 | 2025 | 111 | 0.820 |
Why?
| | Gallbladder Neoplasms | 2 | 2023 | 20 | 0.800 |
Why?
| | Ligation | 12 | 2021 | 92 | 0.790 |
Why?
| | Adenocarcinoma | 6 | 2026 | 931 | 0.790 |
Why?
| | Pancreatitis | 4 | 2026 | 145 | 0.770 |
Why?
| | Adult | 59 | 2026 | 40627 | 0.770 |
Why?
| | Risk Factors | 32 | 2026 | 10816 | 0.660 |
Why?
| | Metastasectomy | 1 | 2021 | 19 | 0.660 |
Why?
| | Liver Transplantation | 5 | 2026 | 827 | 0.640 |
Why?
| | Laparoscopy | 5 | 2026 | 477 | 0.640 |
Why?
| | Clinical Competence | 2 | 2026 | 1247 | 0.640 |
Why?
| | Aged, 80 and over | 21 | 2026 | 8295 | 0.630 |
Why?
| | Propensity Score | 7 | 2026 | 370 | 0.620 |
Why?
| | Practice Patterns, Physicians' | 4 | 2025 | 1358 | 0.620 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 357 | 0.610 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1962 | 0.600 |
Why?
| | Tomography, X-Ray Computed | 6 | 2025 | 2745 | 0.590 |
Why?
| | Carcinoma | 1 | 2021 | 228 | 0.580 |
Why?
| | Treatment Outcome | 27 | 2026 | 11731 | 0.580 |
Why?
| | Lymph Nodes | 6 | 2025 | 502 | 0.580 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2025 | 1148 | 0.570 |
Why?
| | Margins of Excision | 4 | 2026 | 51 | 0.570 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 201 | 0.560 |
Why?
| | Follow-Up Studies | 15 | 2026 | 5431 | 0.550 |
Why?
| | Liver Function Tests | 4 | 2022 | 106 | 0.520 |
Why?
| | Hypertrophy | 5 | 2025 | 127 | 0.520 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 191 | 0.480 |
Why?
| | Hepatitis B virus | 1 | 2016 | 33 | 0.470 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 469 | 0.470 |
Why?
| | Hepatic Artery | 2 | 2026 | 53 | 0.470 |
Why?
| | Adenoviridae Infections | 1 | 2015 | 20 | 0.460 |
Why?
| | Preoperative Care | 4 | 2026 | 382 | 0.440 |
Why?
| | Pancreas | 7 | 2026 | 342 | 0.430 |
Why?
| | Adenoviridae | 1 | 2015 | 199 | 0.430 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 887 | 0.430 |
Why?
| | Mesenteric Veins | 2 | 2025 | 23 | 0.430 |
Why?
| | Prospective Studies | 13 | 2025 | 8011 | 0.430 |
Why?
| | Neoplasm Staging | 7 | 2026 | 1470 | 0.420 |
Why?
| | Cholangitis | 2 | 2025 | 23 | 0.420 |
Why?
| | Common Bile Duct Neoplasms | 2 | 2024 | 27 | 0.410 |
Why?
| | Ampulla of Vater | 2 | 2024 | 39 | 0.410 |
Why?
| | Liver Cirrhosis | 3 | 2025 | 288 | 0.410 |
Why?
| | Postoperative Care | 2 | 2025 | 290 | 0.400 |
Why?
| | Pancreatitis, Chronic | 2 | 2024 | 63 | 0.400 |
Why?
| | Organ Size | 4 | 2025 | 463 | 0.390 |
Why?
| | Perioperative Care | 2 | 2025 | 232 | 0.390 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 335 | 0.380 |
Why?
| | Health Services Accessibility | 1 | 2021 | 1104 | 0.380 |
Why?
| | Scandinavian and Nordic Countries | 5 | 2025 | 14 | 0.370 |
Why?
| | Disease Outbreaks | 1 | 2015 | 422 | 0.360 |
Why?
| | Drainage | 4 | 2026 | 185 | 0.360 |
Why?
| | Leucovorin | 5 | 2025 | 101 | 0.360 |
Why?
| | Registries | 6 | 2026 | 2398 | 0.340 |
Why?
| | Gadolinium DTPA | 4 | 2025 | 70 | 0.330 |
Why?
| | Cholangitis, Sclerosing | 2 | 2021 | 60 | 0.320 |
Why?
| | Serum Albumin | 2 | 2022 | 147 | 0.320 |
Why?
| | Operative Time | 3 | 2026 | 176 | 0.320 |
Why?
| | Magnetic Resonance Imaging | 7 | 2025 | 3888 | 0.310 |
Why?
| | Biliary Tract | 2 | 2021 | 14 | 0.310 |
Why?
| | Biomarkers, Tumor | 3 | 2025 | 1325 | 0.310 |
Why?
| | Fluorouracil | 4 | 2025 | 235 | 0.300 |
Why?
| | Conversion to Open Surgery | 2 | 2026 | 22 | 0.290 |
Why?
| | Delphi Technique | 3 | 2025 | 332 | 0.290 |
Why?
| | Europe | 6 | 2025 | 416 | 0.280 |
Why?
| | Quinolines | 3 | 2026 | 193 | 0.280 |
Why?
| | Hyperamylasemia | 2 | 2026 | 3 | 0.270 |
Why?
| | CA-19-9 Antigen | 2 | 2025 | 34 | 0.270 |
Why?
| | Vascular Surgical Procedures | 3 | 2025 | 340 | 0.260 |
Why?
| | Incidence | 11 | 2026 | 2892 | 0.260 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2026 | 189 | 0.260 |
Why?
| | Blood Loss, Surgical | 2 | 2026 | 112 | 0.260 |
Why?
| | Radionuclide Imaging | 3 | 2022 | 113 | 0.260 |
Why?
| | Intention to Treat Analysis | 2 | 2024 | 80 | 0.250 |
Why?
| | Contrast Media | 4 | 2025 | 491 | 0.250 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 117 | 0.240 |
Why?
| | Surgical Stapling | 1 | 2026 | 16 | 0.240 |
Why?
| | T-Lymphocyte Subsets | 3 | 2024 | 415 | 0.240 |
Why?
| | Mesenteric Artery, Superior | 1 | 2026 | 28 | 0.240 |
Why?
| | X-Ray Microtomography | 1 | 2026 | 107 | 0.240 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 918 | 0.240 |
Why?
| | Indocyanine Green | 2 | 2023 | 42 | 0.240 |
Why?
| | Lymph Node Excision | 2 | 2024 | 174 | 0.230 |
Why?
| | Acute Kidney Injury | 2 | 2025 | 870 | 0.230 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 292 | 0.230 |
Why?
| | CD56 Antigen | 1 | 2025 | 35 | 0.230 |
Why?
| | Survival Analysis | 5 | 2021 | 1386 | 0.230 |
Why?
| | Integrin alpha Chains | 1 | 2025 | 22 | 0.230 |
Why?
| | Bacteremia | 5 | 2013 | 223 | 0.230 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2025 | 20 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 45 | 0.220 |
Why?
| | Hyperbilirubinemia | 1 | 2025 | 11 | 0.220 |
Why?
| | Digestive System Surgical Procedures | 2 | 2024 | 110 | 0.220 |
Why?
| | Estrogen Replacement Therapy | 1 | 2026 | 145 | 0.220 |
Why?
| | Referral and Consultation | 3 | 2026 | 853 | 0.220 |
Why?
| | Ascites | 1 | 2025 | 49 | 0.220 |
Why?
| | Suture Techniques | 1 | 2026 | 131 | 0.220 |
Why?
| | Ablation Techniques | 2 | 2025 | 36 | 0.220 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2025 | 54 | 0.220 |
Why?
| | Postoperative Hemorrhage | 1 | 2026 | 104 | 0.220 |
Why?
| | Diarrhea | 1 | 2026 | 194 | 0.220 |
Why?
| | Gallbladder Diseases | 1 | 2024 | 11 | 0.220 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2025 | 70 | 0.220 |
Why?
| | Intraoperative Complications | 1 | 2026 | 158 | 0.220 |
Why?
| | Failure to Rescue, Health Care | 1 | 2024 | 7 | 0.210 |
Why?
| | Proportional Hazards Models | 3 | 2026 | 1328 | 0.210 |
Why?
| | Positron-Emission Tomography | 1 | 2026 | 343 | 0.210 |
Why?
| | Duodenal Neoplasms | 1 | 2024 | 26 | 0.200 |
Why?
| | Kaplan-Meier Estimate | 3 | 2026 | 967 | 0.200 |
Why?
| | Sarcoma | 1 | 2026 | 205 | 0.200 |
Why?
| | Patient Outcome Assessment | 1 | 2024 | 134 | 0.200 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2023 | 67 | 0.190 |
Why?
| | Menopause | 1 | 2026 | 321 | 0.190 |
Why?
| | Hyperemia | 1 | 2023 | 49 | 0.190 |
Why?
| | Reoperation | 3 | 2026 | 631 | 0.190 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 24 | 0.190 |
Why?
| | Warfare | 1 | 2023 | 101 | 0.190 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2023 | 59 | 0.190 |
Why?
| | Neoplasm Invasiveness | 2 | 2025 | 510 | 0.190 |
Why?
| | Antiviral Agents | 4 | 2015 | 768 | 0.190 |
Why?
| | Carcinoma, Papillary | 1 | 2023 | 79 | 0.180 |
Why?
| | Metformin | 1 | 2026 | 320 | 0.180 |
Why?
| | Imaging, Three-Dimensional | 1 | 2026 | 586 | 0.180 |
Why?
| | alpha 1-Antitrypsin | 1 | 2023 | 102 | 0.180 |
Why?
| | Antigens, CD | 1 | 2025 | 555 | 0.180 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2021 | 20 | 0.180 |
Why?
| | Hemostatics | 1 | 2022 | 61 | 0.180 |
Why?
| | Chemotherapy, Adjuvant | 4 | 2026 | 425 | 0.180 |
Why?
| | Aniline Compounds | 1 | 2022 | 119 | 0.180 |
Why?
| | Hepatic Veins | 2 | 2022 | 32 | 0.180 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 128 | 0.170 |
Why?
| | Fibrinogen | 1 | 2022 | 179 | 0.170 |
Why?
| | Homeostasis | 1 | 2025 | 641 | 0.170 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2021 | 37 | 0.170 |
Why?
| | Glycine | 1 | 2022 | 187 | 0.170 |
Why?
| | DNA, Viral | 3 | 2015 | 358 | 0.170 |
Why?
| | Time Factors | 9 | 2025 | 7186 | 0.170 |
Why?
| | Pancreatic Cyst | 1 | 2021 | 50 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1540 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2013 | 415 | 0.160 |
Why?
| | Mycoses | 2 | 1998 | 88 | 0.160 |
Why?
| | Intraoperative Care | 1 | 2020 | 62 | 0.160 |
Why?
| | Bevacizumab | 1 | 2021 | 168 | 0.160 |
Why?
| | Surgeons | 1 | 2025 | 340 | 0.160 |
Why?
| | Camptothecin | 1 | 2021 | 140 | 0.160 |
Why?
| | Cytomegalovirus Infections | 4 | 1998 | 206 | 0.160 |
Why?
| | Sarcopenia | 1 | 2021 | 91 | 0.150 |
Why?
| | Precancerous Conditions | 1 | 2021 | 166 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 782 | 0.150 |
Why?
| | Patient Care Team | 1 | 2025 | 692 | 0.150 |
Why?
| | Cytokines | 4 | 2025 | 2066 | 0.150 |
Why?
| | Cohort Studies | 6 | 2026 | 5982 | 0.140 |
Why?
| | Bacterial Infections | 2 | 1998 | 246 | 0.140 |
Why?
| | Neutropenia | 2 | 2013 | 155 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2019 | 310 | 0.140 |
Why?
| | Interleukin-6 | 3 | 2022 | 782 | 0.140 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 560 | 0.140 |
Why?
| | Receptors, KIR | 1 | 2019 | 110 | 0.140 |
Why?
| | Risk Assessment | 5 | 2025 | 3686 | 0.140 |
Why?
| | Models, Biological | 1 | 2026 | 1823 | 0.140 |
Why?
| | Hepatocyte Growth Factor | 1 | 2018 | 33 | 0.140 |
Why?
| | Adipose Tissue | 1 | 2022 | 653 | 0.140 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 154 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 232 | 0.130 |
Why?
| | Inflammation | 3 | 2025 | 2881 | 0.130 |
Why?
| | Epidermal Growth Factor | 1 | 2018 | 172 | 0.130 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 1997 | 3 | 0.130 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 464 | 0.130 |
Why?
| | Respirovirus Infections | 1 | 1997 | 14 | 0.130 |
Why?
| | C-Reactive Protein | 1 | 2019 | 420 | 0.130 |
Why?
| | Th2 Cells | 2 | 1997 | 171 | 0.130 |
Why?
| | Influenza B virus | 1 | 1997 | 47 | 0.130 |
Why?
| | Graft Survival | 3 | 1998 | 528 | 0.130 |
Why?
| | Catheter Ablation | 1 | 2021 | 353 | 0.130 |
Why?
| | Thyrotropin | 3 | 2021 | 119 | 0.130 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 923 | 0.130 |
Why?
| | Phenotype | 5 | 2025 | 3172 | 0.120 |
Why?
| | Constriction, Pathologic | 1 | 2017 | 248 | 0.120 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 656 | 0.120 |
Why?
| | Ribavirin | 1 | 1997 | 80 | 0.120 |
Why?
| | Curriculum | 1 | 2024 | 1072 | 0.120 |
Why?
| | Virus Diseases | 2 | 2016 | 216 | 0.120 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1997 | 177 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2026 | 1391 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1568 | 0.120 |
Why?
| | Postoperative Period | 3 | 2023 | 354 | 0.120 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 552 | 0.120 |
Why?
| | Multicenter Studies as Topic | 3 | 2022 | 411 | 0.120 |
Why?
| | Cytosine | 1 | 2015 | 51 | 0.110 |
Why?
| | Logistic Models | 1 | 2021 | 2119 | 0.110 |
Why?
| | Treatment Failure | 1 | 2016 | 365 | 0.110 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 136 | 0.110 |
Why?
| | Hepatitis B | 1 | 2016 | 66 | 0.110 |
Why?
| | Gaucher Disease | 1 | 1995 | 4 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 557 | 0.110 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2118 | 0.110 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 736 | 0.110 |
Why?
| | Gallium Radioisotopes | 2 | 2026 | 16 | 0.110 |
Why?
| | Organophosphonates | 1 | 2015 | 97 | 0.110 |
Why?
| | Opportunistic Infections | 1 | 1995 | 45 | 0.110 |
Why?
| | Sepsis | 2 | 2004 | 641 | 0.110 |
Why?
| | Preoperative Period | 2 | 2025 | 149 | 0.110 |
Why?
| | Japan | 2 | 2025 | 145 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 6079 | 0.100 |
Why?
| | Insulin Resistance | 1 | 2022 | 1243 | 0.100 |
Why?
| | Bilirubin | 2 | 2025 | 100 | 0.100 |
Why?
| | Fungemia | 1 | 2013 | 10 | 0.100 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 89 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1098 | 0.100 |
Why?
| | Cholecystectomy | 2 | 2024 | 60 | 0.100 |
Why?
| | Graft Rejection | 1 | 1997 | 542 | 0.100 |
Why?
| | Amylases | 2 | 2024 | 18 | 0.100 |
Why?
| | ROC Curve | 2 | 2026 | 615 | 0.100 |
Why?
| | Quality of Life | 5 | 2024 | 3197 | 0.100 |
Why?
| | Bile Ducts | 2 | 2024 | 67 | 0.100 |
Why?
| | Graft vs Host Disease | 8 | 2000 | 264 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2013 | 677 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1698 | 0.100 |
Why?
| | Acute Disease | 3 | 2026 | 1031 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2026 | 2652 | 0.090 |
Why?
| | Health Care Surveys | 2 | 2025 | 539 | 0.090 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 847 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5883 | 0.090 |
Why?
| | Evidence-Based Medicine | 2 | 2025 | 737 | 0.090 |
Why?
| | Child, Preschool | 12 | 2013 | 11863 | 0.080 |
Why?
| | Phylogeny | 1 | 2015 | 1020 | 0.080 |
Why?
| | Influenza, Human | 1 | 1997 | 617 | 0.080 |
Why?
| | Lung Diseases, Interstitial | 1 | 1997 | 660 | 0.080 |
Why?
| | Glomerular Filtration Rate | 2 | 2025 | 764 | 0.080 |
Why?
| | Viridans Streptococci | 2 | 2013 | 6 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2018 | 2833 | 0.080 |
Why?
| | Diagnosis, Differential | 2 | 2026 | 1500 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 3085 | 0.070 |
Why?
| | Lymphoproliferative Disorders | 1 | 2009 | 57 | 0.070 |
Why?
| | Heart Failure | 1 | 2022 | 2331 | 0.070 |
Why?
| | Herpesvirus 4, Human | 1 | 2009 | 176 | 0.070 |
Why?
| | Leukemia | 4 | 1998 | 245 | 0.070 |
Why?
| | Anti-Infective Agents | 3 | 2013 | 242 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2009 | 101 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1054 | 0.070 |
Why?
| | Tumor Burden | 2 | 2021 | 323 | 0.060 |
Why?
| | Hematologic Diseases | 2 | 1998 | 66 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2025 | 1103 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2026 | 37 | 0.060 |
Why?
| | Surgical Staplers | 1 | 2026 | 5 | 0.060 |
Why?
| | Infant | 8 | 2013 | 10101 | 0.060 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1984 | 0.060 |
Why?
| | Endopeptidases | 1 | 2026 | 82 | 0.060 |
Why?
| | Norway | 2 | 2016 | 45 | 0.060 |
Why?
| | Acinar Cells | 1 | 2025 | 13 | 0.060 |
Why?
| | Child | 11 | 2013 | 22712 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2025 | 771 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1747 | 0.050 |
Why?
| | Interleukin-15 | 1 | 2025 | 97 | 0.050 |
Why?
| | Germany | 1 | 2025 | 138 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 697 | 0.050 |
Why?
| | Histocompatibility Testing | 4 | 1998 | 121 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2026 | 201 | 0.050 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 134 | 0.050 |
Why?
| | Albumins | 1 | 2025 | 118 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1268 | 0.050 |
Why?
| | Capecitabine | 1 | 2024 | 57 | 0.050 |
Why?
| | Lactates | 1 | 2024 | 83 | 0.050 |
Why?
| | Israel | 1 | 2023 | 46 | 0.050 |
Why?
| | Disease Progression | 2 | 2026 | 2855 | 0.050 |
Why?
| | Paclitaxel | 1 | 2025 | 256 | 0.050 |
Why?
| | Interleukins | 1 | 2025 | 248 | 0.050 |
Why?
| | Adolescent | 10 | 2022 | 22507 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2025 | 221 | 0.050 |
Why?
| | Amphotericin B | 2 | 2013 | 37 | 0.050 |
Why?
| | Estrogens | 1 | 2026 | 381 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 31 | 0.050 |
Why?
| | Keratin-19 | 1 | 2023 | 4 | 0.050 |
Why?
| | Candidiasis | 2 | 2013 | 64 | 0.050 |
Why?
| | Mice | 3 | 2025 | 18394 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 114 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Dipeptidyl Peptidase 4 | 1 | 2022 | 15 | 0.050 |
Why?
| | Hepatomegaly | 1 | 2022 | 4 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2022 | 60 | 0.050 |
Why?
| | Venous Thrombosis | 1 | 2025 | 195 | 0.050 |
Why?
| | Kinetics | 1 | 2026 | 1630 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 479 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 162 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 245 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 225 | 0.050 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 9 | 0.040 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2026 | 439 | 0.040 |
Why?
| | Ceramides | 1 | 2022 | 116 | 0.040 |
Why?
| | Regression Analysis | 1 | 2024 | 1003 | 0.040 |
Why?
| | Accreditation | 1 | 2022 | 101 | 0.040 |
Why?
| | Abdomen | 1 | 2022 | 141 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2023 | 282 | 0.040 |
Why?
| | Gastrectomy | 1 | 2023 | 161 | 0.040 |
Why?
| | Bismuth | 1 | 2021 | 3 | 0.040 |
Why?
| | Animals | 4 | 2025 | 38177 | 0.040 |
Why?
| | Anemia, Aplastic | 3 | 1997 | 42 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 324 | 0.040 |
Why?
| | Endoscopy | 1 | 2024 | 316 | 0.040 |
Why?
| | Population Surveillance | 1 | 2024 | 485 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 460 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 266 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2020 | 223 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 286 | 0.040 |
Why?
| | Neutrophils | 3 | 2021 | 1135 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 193 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1342 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2021 | 255 | 0.040 |
Why?
| | Receptors, KIR2DL3 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytomegalovirus | 2 | 1997 | 168 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2115 | 0.040 |
Why?
| | Asia | 1 | 2019 | 71 | 0.040 |
Why?
| | South America | 1 | 2019 | 57 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 249 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 1998 | 52 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1998 | 51 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 57 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 2 | 2004 | 573 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2020 | 366 | 0.030 |
Why?
| | North America | 1 | 2019 | 312 | 0.030 |
Why?
| | Aspirin | 1 | 2021 | 401 | 0.030 |
Why?
| | Hepatitis, Viral, Human | 1 | 1997 | 20 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1998 | 220 | 0.030 |
Why?
| | Viral Matrix Proteins | 1 | 1997 | 29 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2025 | 3560 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 373 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 1998 | 186 | 0.030 |
Why?
| | Patients | 1 | 2019 | 182 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 676 | 0.030 |
Why?
| | Metabolic Diseases | 2 | 1995 | 114 | 0.030 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 76 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1997 | 67 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 1997 | 200 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1894 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1997 | 182 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 2033 | 0.030 |
Why?
| | Ethanol | 1 | 2021 | 627 | 0.030 |
Why?
| | Young Adult | 3 | 2024 | 14163 | 0.030 |
Why?
| | Eye Neoplasms | 1 | 2016 | 30 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2838 | 0.030 |
Why?
| | Palliative Care | 1 | 2024 | 1012 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 687 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2926 | 0.030 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 220 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1996 | 129 | 0.030 |
Why?
| | 4-Quinolones | 1 | 1995 | 1 | 0.030 |
Why?
| | Splenectomy | 1 | 1995 | 65 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2016 | 86 | 0.030 |
Why?
| | Phosphoproteins | 1 | 1997 | 346 | 0.030 |
Why?
| | Tomography | 1 | 1995 | 45 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1681 | 0.030 |
Why?
| | Anthropometry | 1 | 1995 | 200 | 0.030 |
Why?
| | Administration, Oral | 1 | 1997 | 848 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1496 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 1046 | 0.030 |
Why?
| | Fluconazole | 1 | 2013 | 23 | 0.030 |
Why?
| | Enterococcus | 1 | 2013 | 22 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 26 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2013 | 51 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1800 | 0.020 |
Why?
| | Monocytes | 1 | 1996 | 538 | 0.020 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 70 | 0.020 |
Why?
| | Spleen | 1 | 1995 | 508 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2020 | 2053 | 0.020 |
Why?
| | Hepatitis C | 1 | 1995 | 254 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 854 | 0.020 |
Why?
| | Radiography | 1 | 1995 | 846 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 349 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2019 | 947 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3613 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4284 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 2013 | 169 | 0.020 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1525 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2371 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1996 | 1169 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1996 | 962 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 391 | 0.020 |
Why?
| | Melanoma | 1 | 2016 | 761 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 97 | 0.020 |
Why?
| | Apoptosis | 1 | 1997 | 2430 | 0.020 |
Why?
| | Foscarnet | 2 | 1998 | 20 | 0.020 |
Why?
| | Macrophages | 1 | 1996 | 1514 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 211 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2506 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2009 | 258 | 0.020 |
Why?
| | Viral Load | 1 | 2009 | 527 | 0.020 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1998 | 127 | 0.020 |
Why?
| | Interleukin-1 | 2 | 2004 | 961 | 0.020 |
Why?
| | Bone Marrow | 2 | 1998 | 306 | 0.020 |
Why?
| | Tissue Donors | 2 | 2000 | 426 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2004 | 4155 | 0.010 |
Why?
| | Interleukin-8 | 1 | 2004 | 271 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2000 | 51 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2000 | 42 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2000 | 56 | 0.010 |
Why?
| | Age Factors | 2 | 1998 | 3339 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 2000 | 76 | 0.010 |
Why?
| | Tissue and Organ Harvesting | 1 | 2000 | 73 | 0.010 |
Why?
| | Cadaver | 1 | 2000 | 307 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1217 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 1998 | 29 | 0.010 |
Why?
| | Acyclovir | 1 | 1998 | 96 | 0.010 |
Why?
| | Ganciclovir | 1 | 1997 | 53 | 0.010 |
Why?
| | Leukemia, Myeloid | 1 | 1997 | 48 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 316 | 0.010 |
Why?
| | Probability | 1 | 1997 | 312 | 0.010 |
Why?
| | Exotoxins | 1 | 1996 | 16 | 0.010 |
Why?
| | Streptococcus | 1 | 1996 | 29 | 0.010 |
Why?
| | Lymphokines | 1 | 1996 | 130 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 158 | 0.010 |
Why?
| | CD3 Complex | 1 | 1996 | 111 | 0.010 |
Why?
| | Th1 Cells | 1 | 1996 | 139 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 254 | 0.010 |
Why?
| | Blood Platelets | 1 | 1998 | 400 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 294 | 0.010 |
Why?
| | Biopsy | 1 | 1997 | 1079 | 0.010 |
Why?
| | Anemia | 1 | 1995 | 189 | 0.010 |
Why?
| | Down-Regulation | 1 | 1996 | 627 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1996 | 863 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1996 | 1127 | 0.010 |
Why?
| | Liposomes | 1 | 1993 | 253 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2887 | 0.000 |
Why?
|
|
Sparrelid's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|